Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 448

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 448
---
 and may be exercised at any time until all of the October Pre -FundedWarrants are exercised in full. On October 10, 2024, the Company successfully implemented a restructuring measure by converting the claims of related party debt holders in the amount of $2,788,650 into 493,986 NLS Common Shares. This conversion was facilitated through an ordinary capital increase, providing the necessary shares for the debt holders, and was recorded at fair market value with no gain or loss recognized in the statement of operations. On December4, 2024, we entered into a securities purchase agreement with an accredited investor, providing for the issuance in a private placement offering of 322,580 registered NLS Common Shares, at a purchase price of $3.10 per common share, for aggregate gross proceeds of up to $1million. The offering was structured in two tranches, with the first tranche of $500,000 closing in January 2025 following shareholder approval. The proceeds from the offering were intended to support our general corporate purposes and our proposed Merger with Kadimastem. The second tranche of $500,000 may occur, at the election of the investor, within 15 days following the Company meeting certain conditions, including the receipt of shareholder approval and the NLS Common Shares trading for at least ten consecutive trading days above the purchase price of $3.10, which corresponds to an approximate 15% premium. As of August 28, 2025, the condition for the second tranche has not yet occurred. The Company uses and intends to further use the net proceeds from the offering for working capital and general corporate purposes. On March27, 2025, we entered into a securities purchase agreement, or the March 2025 SPA, with three accredited investors. Pursuant to the terms of the March 2025 SPA, the Company agreed to issue and sell to the investors, in a private placement offering, or the March 2025 Offering, 1,212,122 NLS Preferred Shares with a conversion price of $1.65 per share, as well as warrants to purchase 787,880 NLS Common Shares at an exercise price of $1.80 per share, for aggregate gross proceeds of $2million. The March 2025 Offering initially closed on March28, 2025. Pursuant to 236 the terms of the March 2025 SPA, the investors may purchase up to $1million of additional NLS Preferred Shares on identical terms as the